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ABSTRACT  
This review is virtually focused on the current pandemic (Covid-19) ,  its pathogenesis and recent treatment available till date .As ,we know that 
covid-19, caused by SARS-COV 2 is highly mutating and transmissible virus which has put a new challange for development of vaccines and 
drugs to researchers worldwide. Among Corona virus, SARS-COV 2 is a 7th corona virus which is highly transmissible from human to human and 
no vaccines are available till date, due to this it has become a global threat for human being. It is believed to be zoonotic disease but no clean 
evidence of it main source has been known 
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Background 
The First case of COVID-19 was reported from Wuhan, Hubei 
province, China in late December 2019, where large number 
of patient was admitted to hospital due to pneumonia. Later 
on the causative agent for such a mass scale of pneumonia 
was found to be a viral disease caused by SARS-COV 2, 
similar to SARS-COV 1  but highly transmissible and 
mutagenic.[1] Some scientist believe that it is zoonotic 
disease ,which  spread from bats as genome analysis of novel 
coronavirus sequences revealed that the complete genome 
sequence recognition rates of SARS-CoV 2 and bat SARS 
coronavirus (SARSr-CoV-RaTG13) were 79.5% and 96% 
respectively.[2] Like SARS and MERS causing corona virus, 
COVID-19 causing virus also belong to same class of  virus 
prevalent in nature-β corona virus. WHO declared COVID-19 
outbreak a public Health Emergency of International 
Concern on 30/Jan/2020 and a pandemic on 11 march 
2020.[3] 
Introduction  
COVID-19 was first identified in 2019 at Wuhan and spread 
globally resulting in 2019-2020 global pandemic. COVID-19 
is caused by a β-corona virus (SARS COV-2) which is highly 
transmissible and mutagenic despite of low mortality rate. 
Similar to SARS and MERS disease, the patient infected with 
COVID-19 exhibit viral pneumonia, including fever, difficulty 
breathing, and bilateral lung infiltration in the most severe 
cases.[4] The mortality of the emerging coronavirus of 2019 
seems mainly to be caused by acute respiratory distress 
syndrome (ARDS) [5] which may be associated with 
comorbidities and followed by multiple organ failure leading 
to death [6]. 
Till date researcher has found 7 corona viruses, including 
SARS-Cov 2, they are HCoV-229E, HCoV-NL63, HCoV-OC43, 
HCoV-HKU1, SARS-CoV, and MERS-CoV3.  HCoV-229E and 
HCoV-NL63 belong to the alpha coronavirus, and the others 
include SARS-CoV-2 belong to beta coronavirus.[7] SARS-
CoV and MERS-CoV were considered highly pathogenic that 
transmitted from bats to human via intermediate host palm 
civets and dromedary camels, respectively.[8,9] 
Gastrointestinal aspects of covid-19 
It  has been found that virus of COVID-19 has high affinity to 
angiotenson converting enzyme 2 receptor  (ACE-2)  which 
are also found in epithelial cell of gastrointestinal tract.[10] 
Corona virus has potential to bind to ACE 2 receptor present 
in epithelial cell of GIT to develop symptoms like nausea, 
vomiting, diarrhoea and abdominal pain. Studies has 
identified the presence of corona virus in anal and rectum 
swab and stool specimen of infected person even after the 
clearance of virus from upper respiratory tracts.[11] 
Typically, COVID-19 is a respiratory illness but some patient 
was reported of nausea, vomiting, diarrhoea and abdominal 
pain. In USA, a 35 year old patient infected with corona virus 
has 2 days history of nausea and vomiting, on admit to 
hospital, patient has suffered from diarrhoea and abdominal 
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discomfort from the 2nd day. On day 7, the SARS-CoV-2 RNA 
was detected in stool of the patient by reverse-transcriptase 
polymerase-chain-reaction (RT-PCR).[12]  
In early epidemic, a large study was done, in which data was 
collected from 1,099 patients from 552 hospital of China. It 
reported nausea or vomiting in 55 (5.0%) and diarrhoea in 
42 (3.8%) patients.[13] Several other group have reported 
frequencies of diarrhoea ranging 2.0-10.1%, and nausea and 
vomiting ranging 1.0-10.1%.[14] In Wuhan, a group of 140 
COVID-19  patient was studied were 39.6% was having 
gastrointestinal symptoms, including  nausea 17% , 
diarrhoea 12.9% and vomiting 5%. Similarly the rate of 
diarrhoea in a group of 73 patient was found to be 
35.6%.[15] 
Although at a lower frequency compared to SARS, some 
Covid-19 patients do develop gastrointestinal symptoms 
during their disease course. This suggests that there is 
possibility for a tropism of SARS Cov 2 in gastrointestinal 
tract. Genome sequences showed that SARS-CoV-2 shared 
79.6% sequence identity to SARS-CoV, both encoding and 
expressing the spike (S) glycoprotein that could bind to the 
entry receptor ACE2 to enter human cells. The receptor 
binding domain on SARS-CoV-2 could bind to human ACE2 
with high affinity, correlating with the efficient spread of the 
virus among humans.[16] 
Current clinical features and obstetrical outcomes 
of pregnant women with COVID-19   [17] 
In the epicentre of pandemic in China, Tingji Hospital of 
Tingji Medical College, Huazhong University, Wuhan, 9 cases 
of COVID-19 infected pregnant women was reported whose 
SARS-CoV-2 positivity was confirmed by rt-PCR. The mother 
age varied from 26 to 40 years old. None of them has any 
pre-existing chronic condition like diabetes, hypertension or 
cardiovascular disease. 3 women had co-morbid conditions 
that developed during their pregnancy – influenza (Case 1), 
gestational hypertension occurring since 27 weeks gestation 
(Case 3), and preeclampsia developing at 31 weeks gestation 
(Case 4). Seven women were febrile upon admission; 
additional findings included cough (4/9), myalgia (3/9), sore 
throat (2/9) malaise (2/9), gastrointestinal symptoms (1/9) 
and shortness of breath (1/9). Laboratory test report 
include C-reactive protein (6/9), lymphopenia (5/9), and 
increased alanine aminotransferase 129 (ALT) and aspartate 
amino transferase (AST)(3/9). Lungs with patchy ground-
glass shadows was been demonstrated by 8 of the 9 women. 
None of the women develop pneumonia and there was no 
maternal death. 
All women had a normal birth with no infection of COVID-19 
in a baby.6 cases was tested for SARS CoV-2 virus, sample of 
amniotic fluid, breast milk, umbilical cord blood and 
neonatal throat swab was evaluated- all tests was negative. 
Liver injury in Covid-19 patients 
It has been observed that COVID-19 can cause liver injury, 
while mechanism of action for injury is still not understood. 
It may be due to the direct virus infection at hepatocytes, 
immune-related injury or drug hepatotoxicity. [18] Most of 
the injuries are mild, although severe damage may occur. In 
case of severe condition of COVID-19 patient liver injury was 
reported. In group of 99 patient of COVID-19 in Wuhan 43 
patients had raised ALT or AST; one patient with critical 
Covid-19 had severe hepatitis with serum ALT increased up 
to 7590 U/L.[19] In a group of 56 Covid-19 patients, gamma-
glutamyl transferase (GGT) was elevated in 54% of the 
patients.[20] 
Respiratory system in COVID-19 
Similar to SARS-COV-1, SARS COV-2 also invade the human 
body through ACE2.ACE 2 is an enzyme highly expressed in 
the outer membrane of cells of lungs, arteries, heart, kidney 
and intestine. A human version of enzyme is known as 
hACE2. ACE2 is an essential part of the RAS, and it has 
extensive vascular and organ protection functions in 
hypertension, diabetes, cardiovascular disease, and ARDS. 
[21] The tropism of SARS COV-2 in ACE 2 receptor is due to 
the s-protein spike present in the outer membrane of virus. 
The most severe form of lungs injury is acute respiratory 
distress syndrome(ARDS) which is characterize by  
increased pulmonary vascular permeability and pulmonary 
edema. [22]Patient of COVID-19 rarely suffered from upper 
respiratory symptoms (such as snot, sneezing and sore 
throat) indicating that virus primarily effects lower 
respiratory tracts. [23] 
On 2 Jan 2020, at the epicentre of COVID-19,Wuhan,China 
.41 covid-19 infected patient are admitted ,most of the 
infected person were man (21 out of 41), less than half had a 
underlying disease including diabetes (8), hypertension (6) 
and cardiovascular disease (6). Median age was 49 years. 
Common symptoms at onset of illness were fever (40 of 41 
patients), cough (31), and myalgia or fatigue (18), less 
common symptoms were sputum production (11 of 39), 
headache (3 of 38), haemoptysis (2 of 39), and diarrhoea (1 
of 38). Dyspnoea developed in 22 of 40 patients (median 
time from illness onset to dyspnoea 8·0 days). [24] 
Western treatment of COVID-19 
Covid-19 a viral disease which is caused by SARS COV-2 
virus is a new strain of corona-virus that was identified at 
late December 2019 in Wuhan, China. Since, it is a new virus 
known by mankind there is no vaccines and special 
treatment available for it so far. Development of vaccines 
and drugs in traditional method is a long and tedious 
process. Therefore, there is another option in which a 
systematic and large-scale screening of existing drugs is 
done to see whether they have activity against the COVID-19. 
[25] 
An anti-HIV drug kaletra, which is composed of two protease 
inhibitor, Ritonavir and Liponavir was a recommended by 
the National Health Commission of the People’s Republic of 
China for the treatment of Wuhan pneumonia. [26] It has 
reported that β-coronavirus viral loads of a COVID-19 
patient in Korea significantly decreased after 
lopinavir/ritonavir (Kaletra®, AbbVie, North Chicago, IL, 
USA) treatment.[27] Recently, Remdesivir an antiviral drug 
has also gain some popularity due to good antiviral property 
against a wide array of RNA virus. It has been reported that 
patient treated with remdesivir against COVID-19 has 
achieved good result. [28] Recently China National Center 
for Biotechnology Development has suggested that 
chloroquine in one of three drugs which have a promising 
action in symptomatic treatment of COVID-19, it has been 
reported that patient treated with chloroquine was 
recovered within short duration and symptoms of fever was 
subsided faster and improvement in lungs computed 
tomography (CT) images with no severe adverse effect as 
compared to controlled group. [29] As a result, choroquine is 
used as frontline drugs for the treatment of COVID-19 
worldwide. 
Chinese medical treatment 
The Chinese medicine has also played a major role to 
controlling and recovery from COVID-19 in China. In China 
local government and medical institution has published 
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many medical prescription. The Novel Coronavirus 
Pneumonia Diagnosis and Treatment Plan (6th trial version) 
suggested use of clearing lung and detoxification decoction 
in the clinical treatment. Additionally, clinicians combined 
Chinese and Western medicine treatment including 
lopinavir/ritonavir (Kaletra®), arbidol, and Shufeng Jiedu 
Capsule (SFJDC, a traditional Chinese medicine) and gained 
significant improvement in pneumonia associated symptoms 
in Shanghai Public Health Clinical Center, China. [30] 
 
 
Table 1: Common and potent antiviral drugs. [31] 
Status  Drug Mode of action Anti-infective mechanism Target disease 
Approved Lopinavir/ 
Ritonavir 
Protease inhibitors Inhibiting HIV-1 protease for 
protein cleavage, 
resulting in non-infectious, 
immature viral particles 
HIV/AIDS, SARS, MERS 
Experimental Remdesivir 
(GS-5734) 
Nucleotide analogue 
prodrug 
Interfering with virus post-entry Ebola, SARS, MERS 
Approved, 
Investigational, 
Vet approved 
Chloroquine 9-aminoquinolin Increasing endosomal pH, 
immunomodulating, 
autophagy inhibitors 
Malaria, autoimmune 
disease 
Approved Oseltamivir Neuraminidase 
inhibitor 
Inhibiting the activity of the viral 
neuraminidase 
enzyme, preventing budding from 
the host cell, viral replication, and 
infectivity 
Influenza viruses A 
Approved, 
Investigational 
Ganciclovir Nucleoside analogue Potent inhibitor of the Herpes 
virus family 
including cytomegalovirus 
AIDS-associated 
cytomegalovirus 
infections 
HIV (Human Immunodeficiency Virus). AIDS (Acquired immunodeficiency syndrome) SARS (Severe acute respiratory 
symptoms) MERS (Middle east respiratory symptoms) 
 
Prevention of COVID-19 
Vaccines for a COVID-19 are under clinical trials, which are 
going to prepared within 18 month as per director general of 
WHO, Dr.Tedros. The clinical treatment for COVID-19 until 
now is palliative and supportive treatment. Therefore 
development of vaccines and drugs is very important .As 
COVID-19 is caused by RNA virus. RNA virus related 
vaccines, including measles, polio, encephalitis B virus and 
influenza virus, could be the most promising alternatives. 
And interpersonal transmission of the virus could be 
prevented by immunizing health care workers and non-
infected population. [32] 
The present principles on prevention of COVID-19 are to 
tonify body energy to protect outside body, dispel wind, 
dissipate heat, and dissipate dampness with aromatic agent. 
The six most commonly used Chinese herbal medicines are 
astragalus, liquorice, fangfeng, baizhu and honeysuckle. 
However, the decoction is not suitable for long-term use, and 
the best period is one week only. [33] 
COVID-19 may cause respiratory symptom. Therefore 
vitamin C can be used to prevent it. Patient with pre-existing 
health condition (such diabetes, hypertension, heart disease 
etc.) old age and children are more susceptible for infection 
due to the weak immune system. [34] COVID-19 infection 
can be controlled by choosing healthy lifestyle and 
maintenance personnel hygiene, taking supplementary 
nutrient such as vitamin C could help to boost up immune 
system. For individuals, taking protective measures using 
mask, avoiding social gathering, maintaining social distance, 
washing and sanitizing hand frequently, and avoiding 
touching mouth, eyes, wounds with unwashed hand can 
prevent the spread of infection. [35]. 
Conclusion 
COVID-19 has become a pandemic of 2019-20. This disease 
has become a global threat as no vaccines and drug has been 
developed so far. This disease has infected millions of people 
worldwide and killed thousands of people globally and 
numbers are increasing daily. COVID-19 is highly 
transmissible from human to human, so to control the spread 
of disease many countries are under lockdown including 
India. For current situation, the best way to control the 
spread this infection is maintenance of social hygiene and 
lockdown. The disease has brought a global economic 
slowdown, due to which, environment has got a chance to 
revive itself. Major river of India are cleansing itself, visibility 
has increased, and ozone layer has recovered completely. 
Many pharmaceutical industries all over the world are doing 
their best to develop a vaccines and drug against COVID-19. 
Many techniques like plasma therapy; use of 
hydroxychloroquine has shown good result in controlling the 
current pandemic. 
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